Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;19(2):72-73.
doi: 10.1038/s41584-022-00891-4.

JAK inhibitors: new indication and emerging safety data in 2022

Peter Nash  1
Affiliations

JAK inhibitors: new indication and emerging safety data in 2022

Peter Nash. Nat Rev Rheumatol. 2023 Feb.
No abstract available

PubMed Disclaimer

References

    1. Morand, E. et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. https://doi.org/10.1002/art.42391 (2022). - DOI
    1. Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N. Engl. J. Med. 386, 316–326 (2022). - DOI
    1. Salinas, C. et al. Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases. Rheumatol. Ther. https://doi.org/10.1007/s40744-022-00505-1 (2022). - DOI
    1. Winthrop, K. L. & Cohen, S. B. Oral surveillance and JAK inhibitor safety: the theory of relativity. Nat. Rev. Rheumatol. 18, 301–304 (2022). - DOI
    1. Paik, J. J. et al. Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review. Clin. Exp. Rheumatol. https://doi.org/10.55563/clinexprheumatol/hxin6o (2022). - DOI

LinkOut - more resources